MULTI-OMICS ANALYSIS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ANTI-PD-L1 PLUS ANTI-CTLA-4 AND LOCOREGIONAL THERAPY: CORRELATIVE STUDY OF PHASE2 TRIAL

被引：0
|
作者：
Myojin, Yuta [1 ]
Babei, Sepideh [2 ]
Hoffman, Christoph [2 ]
Kedei, Noemi [1 ]
Ruf, Benjamin [1 ]
Benmebarek, Mohamed-Reda [1 ]
Bauer, Kylynda [1 ]
Huang, Patrick [1 ]
Trehan, Rajiv [1 ]
Ma, Chi [1 ]
Monge, Cecilia [1 ]
Xie, Changqing [1 ]
Armstrong, Paul [3 ]
Duffy, Austin [3 ]
Korangy, Firouzeh [1 ]
Claassen, Manfred [2 ]
Greten, Tim [1 ]
机构：
[1] Natl Canc Inst, Bethesda, MD USA
[2] Univ Tubingen, Tubingen, Germany
[3] Mater Misericordiae Univ Hosp, Dublin, Ireland
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1815
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung
    Chae, Y. K.
    Othus, M.
    Patel, S. P.
    Gerber, D. E.
    Tanvetyanon, T.
    Chung, L. I. -Y.
    Kim, H. S.
    McLeod, C. M.
    Chen, H. X.
    Sharon, E.
    Streicher, H.
    Ryan, C. W.
    Blanke, C. D.
    Kurzrock, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S284 - S285
  • [32] Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
    Patel, Sandip P.
    Othus, Megan
    Chae, Young Kwang
    Huynh, Tridu
    Tan, Benjamin
    Kuzel, Timothy
    McLeod, Christine
    Lopez, Gabby
    Chen, Helen X.
    Sharon, Elad
    Streicher, Howard
    Ryan, Christopher W.
    Blanke, Charles
    Kurzrock, Razelle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 8
  • [33] Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy
    Wilky, B. A.
    Kumthekar, P.
    Wesolowski, R.
    Hwang, J. J.
    Park, S. I.
    Yuan, G.
    Dupont, C. D.
    Lim, M.
    Shebanova, O.
    Cuillerot, J-M.
    Dow, E.
    Ortuzar, W.
    Raizer, J. J.
    Drouin, E.
    Wilson, N.
    Gonzalez, A. M.
    Goldberg, J. M.
    Buell, J. S.
    Stein, R. B.
    Youssoufian, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
    Nakamura, Yasuhiro
    Namikawa, Kenjiro
    Kiniwa, Yukiko
    Kato, Hiroshi
    Yamasaki, Osamu
    Yoshikawa, Shusuke
    Maekawa, Takeo
    Matsushita, Shigeto
    Takenouchi, Tatsuya
    Inozume, Takashi
    Nakai, Yasuo
    Fukushima, Satoshi
    Saito, Shintaro
    Otsuka, Atsushi
    Fujimoto, Noriki
    Isei, Taiki
    Baba, Natsuki
    Matsuya, Taisuke
    Tanaka, Ryo
    Kaneko, Takahide
    Onishi, Masazumi
    Kuwatsuka, Yutaka
    Nagase, Kotaro
    Onuma, Takehiro
    Nomura, Motoo
    Umeda, Yoshiyasu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 78 - 87
  • [35] INTRATUMORAL CORRELATION OF MULTIPLEX IMMUNOFLUORESCENCE AND 89ZR-CREFMIRLIMAB BERDOXAM IMMUNOPET IN RECURRENT GBM PATIENTS TREATED WITH NEOADJUVANT ANTI-PD-1+/- ANTI-CTLA-4 THERAPY
    Markus, Lauren
    Sun, Lu
    Hugo, Willy
    Van den Abbeele, Annick D.
    Wen, Patrick
    Prins, Robert
    NEURO-ONCOLOGY, 2023, 25
  • [36] A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).
    Gao, Jianjun
    Siefker-Radtke, Arlene O.
    Navai, Neema
    Campbell, Matthew T.
    Tidwell, Rebecca Slack
    Guo, Charles
    Kamat, Ashish M.
    Matin, Surena F.
    Araujo, John C.
    Shah, Amishi Yogesh
    Msaouel, Pavlos
    Blando, Jorge M.
    Vence, Luis M.
    Duan, Fei
    Basu, Sreyashi
    Singh, Shalini
    Zhao, Hao
    Allison, James Patrick
    Dinney, Colin P. N.
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.
    Sloan, Andrew E.
    Gilbert, Mark R.
    Zhang, Peixin
    Aldape, Kenneth D.
    Wu, Jing
    Rogers, Lisa R.
    Wen, Patrick Y.
    Barani, Igor J.
    Iwamoto, Fabio Massaiti
    Raval, Raju R.
    Voloschin, Alfredo Daniel
    De Groot, John Frederick
    Won, Minhee
    Mehta, Minesh P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial
    Querfeld, Christiane
    Chen, Lu
    Wu, Xiwei
    Han, Zhen
    Su, ChingYu
    Banez, Melissa
    Quach, Jeralyn
    Barnhizer, Tiffanie
    Crisan, Liliana
    Rosen, Steven T.
    Zain, Jasmine M.
    BLOOD, 2023, 142
  • [39] Multi-time-point [18F]FDG-PET/CT for monitoring a combined anti-PD-L1/anti-CTLA-4 immunotherapy in a murine melanoma model with multiparametric immunohistochemical validation
    Antons, M.
    Kloiber-Langhorst, S.
    Hirner-Eppeneder, H.
    Schaefer, R.
    Stueckl, J.
    Palumbo, G.
    Oos, R.
    Lindner, S.
    Ziegler, S.
    Brendel, M.
    Ricke, J.
    Heimer, M.
    Cyran, C. C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S391 - S391
  • [40] A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.
    Gao, Jianjun
    Siefker-Radtke, Arlene O.
    Navai, Neema
    Campbell, Matthew T.
    Slack, Rebecca
    Guo, Charles
    Kamat, Ashish M.
    Matin, Surena F.
    Papadopoulos, John N.
    Araujo, John C.
    Shah, Amishi Yogesh
    Blando, Jorge M.
    Vence, Luis M.
    Duan, Fei
    Basu, Sreyashi
    Singh, Shalini
    Zhao, Hao
    Dinney, Colin P. N.
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345